Selective A3 adenosine receptor agonist protects against doxorubicin-induced cardiotoxicity

Volume: 77, Issue: 2, Pages: 309 - 322
Published: Dec 16, 2015
Abstract
Doxorubicin (DOX) is an effective anticancer drug; however, its clinical use is limited by its cardiotoxic effect. Adenosine was proved to mediate anti-inflammatory effects and protected from myocardial ischemia/reperfusion injury. So the present work was designed to examine the effectiveness of a selective A3 adenosine receptor agonist (Cl-IB-MECA) in DOX-induced cardiotoxicity and to elucidate the underlying mechanisms via studying its effect...
Paper Details
Title
Selective A3 adenosine receptor agonist protects against doxorubicin-induced cardiotoxicity
Published Date
Dec 16, 2015
Volume
77
Issue
2
Pages
309 - 322
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.